Polyol macrolide antitumor-antibiotics from the marine actinomycete strain CNQ140
View Patent ↗A novel family of cyclic polyene natural products isolated from marine actinomycete strain CNQ140 is provided. This novel strain of actinomycetes was obtained from a previously unstudied population of marine actinomycetes that reside in sediments off La Jolla, Calif. Compounds derived from strain CNQ140 have been characterized as having a cyclic polyene-polyol structure; a molecular weight from about 996 to about 1010 in the core ring structure; and at least 58 carbons and at least 14 oxygens. The invention compounds have antitumor and/or anti-microbial activity.
1. An isolated therapeutic marine actinomycete-derived isolated compound characterized as having
a cyclic polyene-polyol structure comprising at least two aromatic moieties which are phenol derivatives, at least ten unsaturated moieties, and at least ten alcohol groups;
a molecular weight from about 996 to about 1010 in the core ring structure;
at least 58 carbons and at least 14 oxygens;
and antitumor and/or anti-microbial activity, wherein the marine actinomycete is CNQ 140.
2. The compound of claim 1 , wherein the compound has a chemical structure selected from:
3. An article of manufacture comprising:
packaging material; and
a pharmaceutical composition contained within the packaging material, wherein the packaging material includes a label indicating that the pharmaceutical composition includes at least one compound of claim 1 .
4. The article of manufacture of claim 3 , wherein the compound is selected from compounds having a chemical structure
5. An isolated therapeutic marine actinomycete-derived isolated compound having a chemical structure selected from a group consisting of:
6. The compound of claim 5 , wherein the compound is isolated from a cultured marine actinomycete.
7. The compound of claim 5 , wherein the marine actinomycetes is CNQ 140.
8. The compound of claim 5 , wherein the compound is produced bio-synthetically.
9. The compound of claim 5 , wherein the compound has anti-bacterial activity against drug-resistant pathogenic bacteria.
10. The compound of claim 5 , wherein the compound has the degree of antibacterial activity that is at least equal to the degree of antibacterial activity of a macrolide, wherein the macrolide is selected from a group of macrolides that are capable of inhibiting nucleic acid synthesis in pathogenic bacteria.
11. The compound of claim 5 , wherein the compound has antitumor activity against at least one melanoma cancer.
12. An article of manufacture comprising:
packaging material; and
a pharmaceutical composition contained within the packaging material, wherein the packaging material includes a label indicating that the pharmaceutical composition includes at least one compound of claim 5 .
13. The compound of claim 10 , wherein the nucleic acid synthesis in pathogenic bacteria is at the 50S ribosome.